Van ECK Associates Corp Sells 39,625 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Van ECK Associates reduced its Bristol Myers Squibb stake by 39,625 shares in the second quarter, leaving it with 10.22 million shares worth approximately $588.7 million. Institutional investors collectively own 76.41% of BMY.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $66.06 average price target; recent firms initiated or raised coverage with Buy, Strong Buy, or Overweight ratings.
• Bristol Myers Squibb reported quarterly EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion, up 5.7% year over year. The company also maintains a quarterly dividend of $0.63, equivalent to a 3.8% annualized yield.

Van ECK Associates Corp decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,217,590 shares of the biopharmaceutical company's stock after selling 39,625 shares during the period. Van ECK Associates Corp owned 0.50% of Bristol Myers Squibb worth $588,738,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth $25,000. Davis Asset Management L.P. purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth $27,000. Bayban bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BMY. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 27th. Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. TD Cowen started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating for the company. Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an "overweight" rating on the stock. Finally, Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an "equal weight" rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by company insiders.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $66.62 on Friday. The firm has a market capitalization of $136.09 billion, a price-to-earnings ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The business has a 50 day simple moving average of $61.76 and a 200-day simple moving average of $59.68. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the firm posted $1.46 EPS. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.